2型糖尿病与多发性骨髓瘤的关系:事实还是虚构

Q3 Medicine
Ali Rastegar-Kashkouli, Mohsen Jafari, Saina Karami, Pourya Yousefi, A. Taravati, Ashkan Khavaran, Dordaneh Rastegar, Mohammad Reza Jafari, Seyedeh Yasaman Alemohammad, Ghader Dargahi Abbasabad, Mohammad Shahbaz, Mohammad Ebrahimi Kalan
{"title":"2型糖尿病与多发性骨髓瘤的关系:事实还是虚构","authors":"Ali Rastegar-Kashkouli, Mohsen Jafari, Saina Karami, Pourya Yousefi, A. Taravati, Ashkan Khavaran, Dordaneh Rastegar, Mohammad Reza Jafari, Seyedeh Yasaman Alemohammad, Ghader Dargahi Abbasabad, Mohammad Shahbaz, Mohammad Ebrahimi Kalan","doi":"10.34172/npj.2023.10604","DOIUrl":null,"url":null,"abstract":"Multiple myeloma is a plasma cell cancer causing bone and marrow damage, resulting in hypercalcemia, anemia, and renal insufficiency. Diabetes mellitus occurs in 6-24% of multiple myeloma cases, associated with immunosuppression, inflammation, and lymphocyte dysfunction, possibly contributing to multiple myeloma development. Insulin and insulin-like growth factor-1 also contribute to multiple myeloma pathogenesis. The incidence of both multiple myeloma and diabetes mellitus is expected to rise due to the aging population, lifestyle changes, genetic predisposition, and improved diagnostic methods. Although the link between diabetes mellitus and hematological malignancy risk is less conclusive, insulin resistance and growth factors may promote tumor cell proliferation. Genetic variants linked to type 2 diabetes mellitus (T2DM) influence multiple myeloma risks. The insulin like growth factor 1 (IGF1) gene triggers malignant plasma cell proliferation. Additionally, poorly managed T2DM-induced acidosis creates a favorable environment for cancer cell growth, including multiple myeloma. T2DM and metabolic syndrome (MetS) increase multiple myeloma risks through insulin resistance, hyperinsulinemia, inflammation, and dyslipidemia. Inflammatory cytokines [interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin-1β (IL-1β)] contribute to insulin resistance, chronic inflammation, and multiple myeloma cell survival too. The coexistence of diabetes and multiple myeloma presents challenges in managing complications like neuropathy, nephropathy, and retinopathy. In conclusion, the association between T2DM and multiple myeloma has been established, with a discernible influence from distinct genetic variations. Notably, IL-6, TNF-alpha, and IL-1β exert significant influence on the development of insulin resistance and the proliferation of cancer cells, and also their viability. Consequently, the involvement of inflammatory cytokines, dyslipidemia, and IGF1 in the progression of MM among patients with T2DM and MetS is noteworthy.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association between type 2 diabetes mellitus and multiple myeloma: Fact or fiction\",\"authors\":\"Ali Rastegar-Kashkouli, Mohsen Jafari, Saina Karami, Pourya Yousefi, A. Taravati, Ashkan Khavaran, Dordaneh Rastegar, Mohammad Reza Jafari, Seyedeh Yasaman Alemohammad, Ghader Dargahi Abbasabad, Mohammad Shahbaz, Mohammad Ebrahimi Kalan\",\"doi\":\"10.34172/npj.2023.10604\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Multiple myeloma is a plasma cell cancer causing bone and marrow damage, resulting in hypercalcemia, anemia, and renal insufficiency. Diabetes mellitus occurs in 6-24% of multiple myeloma cases, associated with immunosuppression, inflammation, and lymphocyte dysfunction, possibly contributing to multiple myeloma development. Insulin and insulin-like growth factor-1 also contribute to multiple myeloma pathogenesis. The incidence of both multiple myeloma and diabetes mellitus is expected to rise due to the aging population, lifestyle changes, genetic predisposition, and improved diagnostic methods. Although the link between diabetes mellitus and hematological malignancy risk is less conclusive, insulin resistance and growth factors may promote tumor cell proliferation. Genetic variants linked to type 2 diabetes mellitus (T2DM) influence multiple myeloma risks. The insulin like growth factor 1 (IGF1) gene triggers malignant plasma cell proliferation. Additionally, poorly managed T2DM-induced acidosis creates a favorable environment for cancer cell growth, including multiple myeloma. T2DM and metabolic syndrome (MetS) increase multiple myeloma risks through insulin resistance, hyperinsulinemia, inflammation, and dyslipidemia. Inflammatory cytokines [interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin-1β (IL-1β)] contribute to insulin resistance, chronic inflammation, and multiple myeloma cell survival too. The coexistence of diabetes and multiple myeloma presents challenges in managing complications like neuropathy, nephropathy, and retinopathy. In conclusion, the association between T2DM and multiple myeloma has been established, with a discernible influence from distinct genetic variations. Notably, IL-6, TNF-alpha, and IL-1β exert significant influence on the development of insulin resistance and the proliferation of cancer cells, and also their viability. Consequently, the involvement of inflammatory cytokines, dyslipidemia, and IGF1 in the progression of MM among patients with T2DM and MetS is noteworthy.\",\"PeriodicalId\":16388,\"journal\":{\"name\":\"Journal of Nephropharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Nephropharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34172/npj.2023.10604\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nephropharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/npj.2023.10604","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

多发性骨髓瘤是一种浆细胞癌症,可导致骨和骨髓损伤,导致高钙血症、贫血和肾功能不全。糖尿病发生在6-24%的多发性骨髓瘤病例中,与免疫抑制、炎症和淋巴细胞功能障碍有关,可能导致多发性脊髓瘤的发展。胰岛素和胰岛素样生长因子-1也参与多发性骨髓瘤的发病机制。由于人口老龄化、生活方式的改变、遗传易感性和诊断方法的改进,多发性骨髓瘤和糖尿病的发病率预计都会上升。尽管糖尿病与血液系统恶性肿瘤风险之间的联系尚不明确,但胰岛素抵抗和生长因子可能会促进肿瘤细胞增殖。与2型糖尿病(T2DM)相关的遗传变异影响多发性骨髓瘤的风险。胰岛素样生长因子1(IGF1)基因触发恶性浆细胞增殖。此外,管理不善的T2DM诱导的酸中毒为癌症细胞生长(包括多发性骨髓瘤)创造了有利的环境。T2DM和代谢综合征(MetS)通过胰岛素抵抗、高胰岛素血症、炎症和血脂异常增加了多发性骨髓瘤的风险。炎症细胞因子[白细胞介素6(IL-6)、肿瘤坏死因子-α(TNF-α)和白细胞介蛋白-1β(IL-1β)]也有助于胰岛素抵抗、慢性炎症和多发性骨髓瘤细胞存活。糖尿病和多发性骨髓瘤的共存对神经病变、肾病和视网膜病变等并发症的管理提出了挑战。总之,T2DM与多发性骨髓瘤之间的联系已经确立,其明显的影响来自不同的遗传变异。值得注意的是,IL-6、TNF-α和IL-1β对胰岛素抵抗的发展和癌症细胞的增殖及其生存能力产生显著影响。因此,炎性细胞因子、血脂异常和IGF1在T2DM和MetS患者MM进展中的参与是值得注意的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Association between type 2 diabetes mellitus and multiple myeloma: Fact or fiction
Multiple myeloma is a plasma cell cancer causing bone and marrow damage, resulting in hypercalcemia, anemia, and renal insufficiency. Diabetes mellitus occurs in 6-24% of multiple myeloma cases, associated with immunosuppression, inflammation, and lymphocyte dysfunction, possibly contributing to multiple myeloma development. Insulin and insulin-like growth factor-1 also contribute to multiple myeloma pathogenesis. The incidence of both multiple myeloma and diabetes mellitus is expected to rise due to the aging population, lifestyle changes, genetic predisposition, and improved diagnostic methods. Although the link between diabetes mellitus and hematological malignancy risk is less conclusive, insulin resistance and growth factors may promote tumor cell proliferation. Genetic variants linked to type 2 diabetes mellitus (T2DM) influence multiple myeloma risks. The insulin like growth factor 1 (IGF1) gene triggers malignant plasma cell proliferation. Additionally, poorly managed T2DM-induced acidosis creates a favorable environment for cancer cell growth, including multiple myeloma. T2DM and metabolic syndrome (MetS) increase multiple myeloma risks through insulin resistance, hyperinsulinemia, inflammation, and dyslipidemia. Inflammatory cytokines [interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin-1β (IL-1β)] contribute to insulin resistance, chronic inflammation, and multiple myeloma cell survival too. The coexistence of diabetes and multiple myeloma presents challenges in managing complications like neuropathy, nephropathy, and retinopathy. In conclusion, the association between T2DM and multiple myeloma has been established, with a discernible influence from distinct genetic variations. Notably, IL-6, TNF-alpha, and IL-1β exert significant influence on the development of insulin resistance and the proliferation of cancer cells, and also their viability. Consequently, the involvement of inflammatory cytokines, dyslipidemia, and IGF1 in the progression of MM among patients with T2DM and MetS is noteworthy.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Nephropharmacology
Journal of Nephropharmacology Medicine-Pharmacology (medical)
CiteScore
1.70
自引率
0.00%
发文量
18
审稿时长
4 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信